For decades, the term “incurable disease” represented an impenetrable barrier in medical science — a phrase where hope seemed to vanish as soon as it was uttered. But as 2026 unfolds, artificial intelligence (AI) is beginning to crack that wall, bringing new possibilities for treatment and prevention.
In today’s AI-powered world, researchers are no longer just treating symptoms—they are redefining the rules of medicine. From folding proteins in seconds to designing personalized therapies for rare cancers, AI is transforming laboratories from trial-and-error spaces into realms of “bio-digital certainty.”
AI is ending decades of stagnation in antibiotic development. Traditional drug discovery has been slow and costly; between 2017 and 2022, only 12 new antibiotics were approved, most of which proved ineffective against resistant bacteria. Antibiotic-resistant “superbugs” are now responsible for 5 million deaths annually and are projected to cause over $2.5 trillion in global economic disruption by 2050.
AI models can now screen billions of compounds in days, identifying entirely new chemical structures. Researchers at MIT recently designed two compounds using AI that show promise against highly drug-resistant Neisseria gonorrhoeae and MRSA (methicillin-resistant Staphylococcus aureus). AI can also perform “freestyle” molecular design, narrowing down millions of possibilities in hours rather than years.
Previously, AI has aided in discovering antibiotics effective against Clostridium difficile and Mycobacterium tuberculosis, opening new frontiers in combating infectious diseases.
After 200 years of research, an effective treatment to slow Parkinson’s disease progression remained elusive. Worldwide, 10 million people live with the disease, including 1 million in the US.
Researchers at the University of Cambridge, led by Professor Michele Vendruscolo, are now using AI to target Lewy bodies, misfolded protein clumps that trigger early neurodegeneration. By screening billions of molecules rapidly, AI has identified compounds that stabilize proteins before misfolding occurs. Lab tests show AI-suggested molecules outperform conventional approaches, offering hope to prevent Parkinson’s rather than merely treat it.
AI is also unlocking the potential of existing medications. Dr. David Fajgenbaum of the University of Pennsylvania demonstrated that thousands of approved drugs could be repurposed to treat conditions they weren’t originally intended for, even saving his own life. New AI models are mapping 8,000 approved drugs against 17,000 diseases, including rare disorders like Pitt–Hopkins syndrome, sarcoidosis, and certain kidney cancers.
At McGill University, AI is being used to simulate Idiopathic Pulmonary Fibrosis (IPF) progression. By sequencing lung cells at different disease stages, AI can model how cells deteriorate and test potential drug effects virtually before clinical trials.
Decades of effort went into mapping single 3D protein structures. In 2022, AlphaFold 2 predicted the 3D shapes of nearly 200 million known proteins. Now, AlphaFold 3 can model DNA, RNA, and ligands, predicting how drugs interact with protein pockets, accelerating drug design dramatically.
Despite AI’s revolutionary impact, challenges remain. Critical data on drug absorption and toxicity is often proprietary, and while AI excels in initial screening and target identification, drugs still require years of human clinical trials.
“AI is transforming drug discovery, but only in very specific ways,” says Vendruscolo. Nonetheless, the technology is steadily turning the concept of “incurable” into a realm of scientific optimism and possibility.
